Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials
Crossref DOI link: https://doi.org/10.1007/s11060-015-1791-4
Published Online: 2015-04-29
Published Print: 2015-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Carlson, Julie A.
Reddy, Krishna
Gaspar, Laurie E.
Ney, Douglas
Kavanagh, Brian D.
Damek, Denise
Lillehei, Kevin
Chen, Changhu
Text and Data Mining valid from 2015-04-29